<DOC>
	<DOCNO>NCT02052141</DOCNO>
	<brief_summary>Primary Objective - To assess relative efficacy two dose level CINRYZE ( 500 Units 1000 Units ) administer intravenous ( IV ) injection every 3 4 day prevent angioedema attack child 6 11 year age hereditary angioedema ( HAE ) . Secondary Objectives - To assess safety tolerability , characterize pharmacokinetics ( PK ) pharmacodynamics ( PD ) , assess immunogenicity two dose level CINRYZE administer IV injection child 6 11 year age HAE .</brief_summary>
	<brief_title>Safety Efficacy Study CINRYZE Prevention Angioedema Attacks Children Ages 6-11 With Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Diagnosis Type I Type II HAE . History angioedema attack . History bleed clot abnormality . Diagnosis acquire angioedema know C1 INH antibody . History allergic reaction C1 esterase inhibitor blood product . Receipt experimental agent require prevention treatment angioedema attack within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>C1 inhibitor</keyword>
	<keyword>HAE</keyword>
	<keyword>Cinryze</keyword>
	<keyword>C1 INH</keyword>
	<keyword>Prevention</keyword>
</DOC>